ValuEngine upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a hold rating to a buy rating in a research note issued to investors on Monday morning.
Several other equities analysts also recently weighed in on the stock. Goldman Sachs upgraded shares of Alnylam Pharmaceuticals from a buy rating to a conviction-buy rating in a research note on Friday, December 15th. Leerink Swann lifted their target price on shares of Alnylam Pharmaceuticals from $132.00 to $135.00 and gave the stock a market perform rating in a research note on Thursday, January 25th. BidaskClub downgraded shares of Alnylam Pharmaceuticals from a buy rating to a hold rating in a research note on Thursday, December 7th. B. Riley reiterated a buy rating and issued a $205.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, January 19th. Finally, Morgan Stanley reduced their price objective on shares of Alnylam Pharmaceuticals from $128.00 to $118.00 and set an equal weight rating for the company in a research note on Friday, February 9th. Four investment analysts have rated the stock with a sell rating, four have assigned a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $134.15.
ALNY opened at $102.29 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.23 and a current ratio of 12.23. Alnylam Pharmaceuticals has a twelve month low of $46.90 and a twelve month high of $153.99.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share for the quarter, missing the consensus estimate of ($1.38) by ($0.10). The business had revenue of $37.90 million during the quarter, compared to analysts’ expectations of $19.31 million. Alnylam Pharmaceuticals had a negative return on equity of 41.08% and a negative net margin of 545.95%. Alnylam Pharmaceuticals’s revenue for the quarter was up 116.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.32) EPS. analysts anticipate that Alnylam Pharmaceuticals will post -6.88 EPS for the current year.
In other Alnylam Pharmaceuticals news, Director Philip A. Sharp sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $129.00, for a total transaction of $1,935,000.00. Following the completion of the sale, the director now directly owns 155,795 shares in the company, valued at $20,097,555. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Laurie Keating sold 20,000 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $145.00, for a total transaction of $2,900,000.00. Following the sale, the senior vice president now owns 24,500 shares of the company’s stock, valued at $3,552,500. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 198,620 shares of company stock valued at $28,404,143. 4.30% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. lifted its position in Alnylam Pharmaceuticals by 16.4% during the fourth quarter. BlackRock Inc. now owns 7,115,063 shares of the biopharmaceutical company’s stock valued at $903,969,000 after purchasing an additional 1,003,366 shares during the last quarter. UBS Asset Management Americas Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 2.2% in the 4th quarter. UBS Asset Management Americas Inc. now owns 1,394,213 shares of the biopharmaceutical company’s stock worth $177,135,000 after acquiring an additional 29,816 shares during the last quarter. Gilder Gagnon Howe & Co. LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 8.6% in the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 1,217,367 shares of the biopharmaceutical company’s stock worth $154,666,000 after acquiring an additional 96,812 shares during the last quarter. Orbimed Advisors LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 69.7% in the 3rd quarter. Orbimed Advisors LLC now owns 1,084,800 shares of the biopharmaceutical company’s stock worth $127,453,000 after acquiring an additional 445,600 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 13.4% in the 4th quarter. Geode Capital Management LLC now owns 747,646 shares of the biopharmaceutical company’s stock worth $94,929,000 after acquiring an additional 88,119 shares during the last quarter. Institutional investors and hedge funds own 92.28% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/05/alnylam-pharmaceuticals-alny-upgraded-at-valuengine.html.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.